A specific kind of cancer known as Leukemia, which affects blood and bone marrow had long been a subject of research and experiments for the doctors, since they were unable to find a proper treatment for it. But the British drug maker GlaxoSmithKline PLC on Thursday announced through a statement that its new experimental leukemia drug has shown positive results for patients who didn’t respond well to any other medication.
To reach the conclusion, the reactions of almost 140 patients were recorded after they had been administered the ofatumumab treatment. The more worrying thing is that patients, who have chronic lymphocytic leukemia (CLL), are also prone to both fludarabine and alemtuzumab.